(R)-2(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogenphosphate | 1384984-31-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (R)-2(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogenphosphate
• 英文别名: (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1Hbenzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate；(R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphoric acid；Fobrepodacin；2-[5-[2-(ethylcarbamoylamino)-6-fluoro-7-[(2R)-oxolan-2-yl]-3H-benzimidazol-5-yl]pyrimidin-2-yl]propan-2-yl dihydrogen phosphate
• CAS: 1384984-31-9
• 化学式: C₂₁H₂₆FN₆O₆P
• 分子量: 508.446
• InChiKey: COTQDURISRILOR-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  172
• 氢给体数：
  5
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (R)-2(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogenphosphate 在 sodium hydroxide 作用下， 生成 disodium (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate
  参考文献：
  名称：

  Evaluation of WO2012177707 and WO2012097269: Vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents

  摘要：

  The two patent applications describe two novel compounds in the benzimidazole class of GyrB/ParE antibacterial agents and multiple phosphate prodrugs derived from these compounds. The new benzimidazole compounds have excellent antibacterial activity on Gram-positive strains. But like previous benzimidazoles, they have limited solubility and are highly protein bound. The phosphate prodrugs offer a drug substance with high aqueous solubility that should aid both intravenous and oral formulations. The potential utility of the prodrugs was demonstrated in efficacy studies.

  DOI：

  10.1517/13543776.2013.820707
• 作为产物：
  描述：

  2-溴-3-氟硝基苯 在 四氮唑 、 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 di-μ-bromobis(tri-tert-butylphosphine)dipalladium(I) 、 硫酸 、 5%-palladium/activated carbon 、 palladium on activated charcoal 、 氢气 、 sodium acetate 、 碳酸氢钠 、 三乙胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 甲基叔丁基醚 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， -15.0~60.0 ℃ 、344.75 kPa 条件下， 反应 174.16h， 生成 (R)-2(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogenphosphate
  参考文献：
  名称：

  [EN] SOLID FORMS OF (R)-2-(5-(2-(3-ETHYLUREIDO)-6-FLUORO-7-(TETRAHYDROFURAN-2-YL)-1H-BENZO[D]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE AND SALTS THEREOF
  [FR] FORMES SOLIDES DE (R)-2-(5-(2-(3-ÉTHYLUREIDO)-6-FLUORO-7-(TÉTRAHYDROFURAN-2-YL)-1H-BENZO[D]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE ET SES SELS

  摘要：

  该发明涉及公式（I）的固体形式，其中X为-PO（OH）2，-PO（OH）O-M+或-PO（O-）2⋅2M+，其中M是单价阳离子，例如Na+，K+，Li+或NH4+。该发明还提供了药学上可接受的组合物，其中包括该化合物的固体形式，并且提供了使用该组合物治疗各种疾病的方法。

  公开号：

  WO2014015105A1

文献信息

• GYRASE AND TOPOISOMERASE IV INHIBITORS
  申请人：Le Tiran Arnaud

  公开号：US20120184512A1

  公开（公告）日：2012-07-19

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

  本发明涉及公式(I)的化合物或其药用盐，其中X和R如本文所定义。公式(I)的化合物可用作治疗细菌感染的旋转酶和/或拓扑异构酶IV抑制剂。公式(I)的化合物具有广泛的抗菌活性和有利的毒理学特性，或者是具有该活性的化合物的前药。
• [EN] COMBINATION THERAPY COMPRISING|1 -ETHYL-3-[5-[2-{1 -HYDROXY-1 -METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRA HYDROFURAN-2-|YL}-1 H-BENZIMIDAZOL-2-YL]UREA AND DERIVATIVES THEREOF TO TREAT MYCOBACTERIUM|DISEASES<br/>[FR] THÉRAPIE COMBINÉE COMPRENANT DE LA 1-ÉTHYL-3[5-[-2-{1-HYDROXY-1-MÉTHYL-ÉTHYL}PYRIMIDIN-5-YL]-7-(TÉTRAHYDROFURAN-2-YL}-1H-BENZIMIDAZOL-2-YL]URÉE ET SES DÉRIVÉS POUR TRAITER DES MALADIES MYCOBACTÉRIENNES
  申请人：VERTEX PHARMA

  公开号：WO2014014845A1

  公开（公告）日：2014-01-23

  The present invention relates to combination therapies comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

  本发明涉及组合疗法，包括公式(I)化合物或其药学上可接受的盐，其中X和R如本文所定义。公式(I)化合物可用作革兰氏阴性菌和/或拓扑异构酶IV抑制剂，用于治疗细菌感染。公式(I)化合物具有广泛的抗菌活性和优越的毒理学特性，或是具有该活性的化合物的前药。
• [EN] PYRIMIDINE GYRASE AND TOPOISOMERASE IV INHIBITORS<br/>[FR] INHIBITEURS DE PYRIMIDINE GYRASE ET TOPOÏSOMÉRASE IV
  申请人：VERTEX PHARMA

  公开号：WO2012097269A1

  公开（公告）日：2012-07-19

  The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti¬ bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

  本发明涉及一种公式(I)的化合物或其药学上可接受的盐，其中X和R如本文所定义。公式(I)的化合物对于治疗细菌感染作为陀螺酶和/或拓扑异构酶IV抑制剂是有用的。公式(I)的化合物具有广泛的抗菌活性和优良的毒理学特性，或者是具有该活性的化合物的前药。
• SOLID FORMS OF (R)-2-(5-(2-(3-ETHYLUREIDO)-6-FLUORO-7-(TETRAHYDROFURAN-2-YL)-1H-BENZO[d]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE AND SALTS THEREOF
  申请人：O'DOWD Hardwin

  公开号：US20140031318A1

  公开（公告）日：2014-01-30

  The invention relates to solid forms of the Formula (I) wherein X is —PO(OH) 2 , —PO(OH)O − M + , or —PO(O − ) 2 .2M + , wherein M is a monovalent cation such as Na + , K + , Li + , or NH 4 + . The invention also provides pharmaceutically acceptable compositions comprising the solid form of the compound and method of using the compositions in the treatment of various disorders.

  本发明涉及公式（I）的固态形式，其中X为—PO（OH）2，—PO（OH）O−M+或—PO（O−）2.2M+，其中M是一价阳离子，例如Na+，K+，Li+或NH4+。本发明还提供了药学上可接受的组合物，包括该化合物的固态形式，并提供了使用这些组合物治疗各种疾病的方法。
• COMBINATION THERAPY TO TREAT MYCOBACTERIUM DISEASES
  申请人：Locher Christopher Phillip

  公开号：US20140045791A1

  公开（公告）日：2014-02-13

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

  本发明涉及式(I)化合物或其药学上可接受的盐，其中X和R的定义如本文所述。式(I)化合物可用作抑制DNA旋转酶和/或拓扑异构酶IV的抑制剂，用于治疗细菌感染。式(I)化合物具有广泛的抗菌活性和优越的毒理学特性，或者是具有该活性的前药。